Fig. 3: DILI toxicity testing platform based on HepG2 spheroid models.
From: Development of an AI model for DILI-level prediction using liver organoid brightfield images
a Brightfield morphology changes (12 original images and 1 stacked image) of liver injury in HepG2 spheroids exposed to Hydrocortisone (with a label of No-DILI levels) from Day 0 to Day 3. b ALB inhibition (P = 0.0073, t = 5.039) and ATP inhibition (P = 0.0080, t = 4.900) of liver injury in HepG2 spheroids exposed to Hydrocortisone at end of Day 3. c Brightfield morphology changes (12 original images and 1 stacked image) of liver injury in HepG2 spheroids exposed to Cyclophosphamide (with a label of Less-DILI levels) from Day 0 to Day 3. d ALB inhibition (P = 0.0045, t = 5.750) and ATP inhibition (P = 0.0080, t = 4.899) of liver injury in HepG2 spheroids exposed to Cyclophosphamide at end of Day 3. e Brightfield morphology changes (12 original images and 1 stacked image) of liver injury in HepG2 spheroids exposed to Travafloxacin (with a label of Most-DILI levels) from Day 0 to Day 3. f ALB inhibition (P = 0.0564, t = 2.661) and ATP inhibition (P < 0.0001, t = 21.46) of liver injury in HepG2 spheroids exposed to Travafloxacin at end of Day 3. Scale bar = 100 μm. **P < 0.01; ****P < 0.0001. Error bars represent mean ± SD across n = 3 biologically independent organoid samples. Cohen’s d and 95% CI are provided in Supplementary Table 6.
